 This study will enroll HIV-uninfected men who have sex with men and transgender women MSMTGW and women who have sex with men WSM. Participation will last 34 weeks. All participants will be given a combination pill that contains FTCTDF. For the first 5 weeks, all participants will come to the study clinic weekly to receive a single dose of FTCTDF. 